The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥18 in Germany
Year: 2026
Type: article
Abstract: BACKGROUND: Significant residual burden of invasive pneumococcal disease (IPD) is attributable to Streptococcus pneumoniae serotypes not included in any available vaccines in Germany. This study quantified the burden of invasive pneumococcal disease attributable to PCV21 and PCV20 serotypes among German adults. RESEARCH DESIGN AND METHODS: A published state-transition Markov model estimated the lifetime cases, deaths, and direct costs (2023 Euros) of IPD by age (18-49, 50-59, and 60 years and older) and risk group (low-risk, at-risk, and high-risk) in Germany. One-way sensitivity analysis on PCV21 cost was conducted. RESULTS: Across all age groups, there were 50,462 more IPD cases and 8895 deaths attributable to the serotypes in PCV21 compared to PCV20. The eight unique serotypes to PCV21 accounted for approximately 22% of disease. Higher direct costs were associated with PCV21 serotypes versus PCV20 serotypes (€505,094,685 versus €389,835,550, respectively). Discount rate of costs was the most influential input. CONCLUSIONS: Serotypes in PCV21 compared to PCV20 are associated with greater health and economic burden in Germany, primarily driven by the eight unique serotypes included in PCV21 and no other licensed vaccine. Including PCV21 in the national German vaccination guidelines may substantially reduce IPD-related health and economic burden among adults.
Source: Expert Review of Vaccines
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7123402609